MHRA advice on rosiglitazone
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a statement following the publication of a meta-analysis in the New England Journal of Medicine linking rosiglitazone with cardiovascular events.
The publication of the original paper has already been covered, as has the FDA response to the study.
The MHRA have highlighted that the product information for rosiglitazone has carried warnings about heart failure since 2000 and myocardial infarction since 2006.
The MHRA advice is that "patients should not stop treatment with rosiglitazone but should discuss their medication with their doctor at their next routine appointment".
Action: Clinicians should be aware of the MHRA advice and discuss alternative treatment options with patients currently taking rosiglitazone at their next routine appointment.
« May NICE Guidance | Decision Aids may improve compliance » |
[…] fails to provide any reassurance with respect to the cardiovascular safety of rosiglitazone. MHRA advice recommends that patients currently taking rosiglitazone discuss the risks and benefits of continued […]
Pingback by Rosiglitazone defence unconvincing | Prescribing Advice for GPs — June 6, 2007 #